Cogent Biosciences, Inc.

NasdaqGS COGT

Cogent Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 335.52 M

Cogent Biosciences, Inc. Cash and Short-Term Investments is USD 335.52 M for the quarter ending September 30, 2024, a 7.25% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Cogent Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 312.83 M, a 8.21% change year over year.
Cogent Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 289.09 M, a 42.49% change year over year.
Cogent Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 202.89 M, a 56.77% change year over year.
Cogent Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 129.42 M, a 182.07% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: COGT

Cogent Biosciences, Inc.

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive
Employees	164
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years